Abstract:Repurposing identified Food and Drug Administration‐approved drug‐biomarker combinations with high sensitivity and specificity. In a real‐world dataset, repurposing identified novel drug‐biomarker combinations in patients who were ineligible for standard therapies or biomarker‐matched trials. Preliminary functional validation was demonstrated for two drug‐biomarker combinations. Using The Cancer Genome Atlas data, the potential scope of repurposing was identified. Purpose Systematic repurposing of approved medicines for another indication may accelerate drug development in oncology. We present a strategy combining biomarker testing with drug repurposing to identify new treatments for patients with advanced cancer. Methods Tumours were sequenced with the Illumina TruSight Oncology 500 (TSO‐500) platform or the FoundationOne CDx panel. Mutations were screened by two medical oncologists and pathogenic mutations were categorised referencing literature. Variants of unknown significance were classified as potentially pathogenic using plausible mechanisms and computational prediction of pathogenicity. Gain of function (GOF) mutations were evaluated through repurposing databases Probe Miner (PM), Broad Institute Drug Repurposing Hub (Broad Institute DRH) and TOPOGRAPH. GOF mutations were repurposing events if identified in PM, not indexed in TOPOGRAPH and excluding mutations with a known Food and Drug Administration (FDA)‐approved biomarker. The computational repurposing approach was validated by evaluating its ability to identify FDA‐approved biomarkers. The total repurposable genome was identified by evaluating all possible gene‐FDA drug‐approved combinations in the PM dataset. Results The computational repurposing approach was accurate at identifying FDA therapies with known biomarkers (94%). Using next‐generation sequencing molecular reports (n = 94), a meaningful percentage of patients (14%) could have an off‐label therapeutic identified. The frequency of theoretical drug repurposing events in The Cancer Genome Atlas pan‐cancer dataset was 73% of the samples in the cohort. Conclusion A computational drug repurposing approach may assist in identifying novel repurposing events in cancer patients with no access to standard therapies. Further validation is needed to confirm a precision oncology approach using drug repurposing.

In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach

High throughput in vivo phenotypic screening for drug repurposing: Discovery of MLR-1023 a novel insulin sensitizer and novel Lyn kinase activator with clinical proof of concept

Phenotypic screening of low molecular weight compounds is rich ground for repurposed, on-target drugs

A Pathway Profile-Based Method for Drug Repositioning

A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

Current approaches in identification of a novel drug targets for drug repurposing

A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery

Integrating population-level and cell-based signatures for drug repositioning

Screening Strategies and Methods for Better Off-Target Liability Prediction and Identification of Small-Molecule Pharmaceuticals

Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases

Artificial Intelligence/Machine Learning-Driven Small Molecule Repurposing via Off-Target Prediction and Transcriptomics

Drug Repurposing: Far Beyond New Targets for Old Drugs

Drug Repurposing: A Leading Strategy for New Threats and Targets

Phenotypic approaches for CNS drugs

Repositioning Drugs For Breast Cancer Based On The Identification Of Cancer Related Signaling Pathways

PHDs-seq: a Large-Scale Phenotypic Screening Method for Drug Discovery Through Parallel Multi-Readout Quantification

Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning

In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA library

The Trabectedin Case

System biology approaches for drug repurposing